1391P Phase III confirmatory efficacy and safety study of proposed bevacizumab biosimilar (MYL-1402O) compared with avastin, in the first-line treatment of patients with stage IV non-squamous non-small cell lung cancer (nsNSCLC)

Autor:	Cornelius F. Waller, I. Bondarenko, Ashwini Vishweswaramurthy, G. Ranganna, Mark A. Socinski, T. Idris, Alexander Luft, K. Beckmann, Abhijit Barve, Subramanian Loganathan
Rok vydání:	2020
Předmět:	Oncology medicine.medical_specialty Bevacizumab business.industry Biosimilar Hematology medicine.disease First line treatment Non squamous Internal medicine Medicine Non small cell Stage iv business Lung cancer medicine.drug
Zdroj:	Annals of Oncology. 31:S883-S884
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2020.08.1705
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::8b6ab1b28e13eed71807fb11a875d84e https://doi.org/10.1016/j.annonc.2020.08.1705 Zobrazit plný text záznamu